Meng S, Berna R, Hoffstad O, Takeshita J, Shin D, Chiesa Fuxench ZC, Margolis DJ Epithelial Barrier Diseases Among Adult Patients with Seborrheic Dermatitis , JAMA Dermatol, 162(1): 2026,15-23
Chiesa Fuxench ZC, Lai Z, Kuo Y, Nawaz H, Cotliar J. Ruxolitinib cream monotherapy for facial and/or neck atopic dermatitis: results from a decentralized, randomized phase 2 clinical trial , J Dermatolog Treat, 36(1): 2025,2480744
Narla S, Chiesa Fuxench ZC, Abuabara K, Beck LA, Chovatiya R, Thaçi D, Silverberg J What Does Long-Term Control in Atopic Dermatitis Look Like , Dermatitis, 36(6): 2025,583-600
Chiesa Fuxench ZC, Wan J, Wang S, Syed MN, Shin DB, Abuabara K, Lemeshow AR, Gelfand JM Fracture risk among adults with atopic dermatitis: A population-based cohort study in the United Kingdom , J Eur Acad Dermatol Venereol, 39(9): 2025,e816-e819
Rau A, Leahr G, Del Pozo D, Hoffstad O, Chiesa Fuxench ZC, Grice E, Margolis DJ Atopic Dermatitis: Association of maternal and child history of celiac disease and the child's development of atopic dermatitis , J Am Acad Dermatol, 92(6): 2025,1385-87
Silva GS, Gotschall JW, Hu F, Whidden E, Cunningham P, Niculcea J, Chapman C, Sharma PV, Evans G, Hussain F, Chiesa Fuxench ZC, Knox K, Rosenbach M An Educational Intervention to Reduce Regulated Medical Waste: The Inpatient Medicine and Outpatient Dermatology Setting , Int J Dermatol, 64(5): 2025,901-08
Kenney HM, Yoshida T, Berdyshev E, Calatroni A, Gill SR, Simpson EL, Lussier S, Boguniewicz M, Hata T, Chiesa Fuxench ZC, De Benedetto A, Ong PY, Ko J, Davidson W, David G, Schlievert PM, Leung DYM, Beck LA CERS1 is a biomarker of Staphylococcus aureus abundance and atopic dermatitis severity , J Allergy Clin Immunol, 155(2): 2025,479-90
Ständer S, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Metz M, Tsianakas A, Pink A, Fage S, Micali G, Weisshaar E, Sundaram H, Metelitsa A, Augustin M, Wollenberg A, Homey B, Fargnoli MC, Sofen H, Korman NJ, Skov L, Chen X, Jabbar-Lopez ZK, Piketty C, Kwatra SG; OLYMPIA 1 Investigators Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial , JAMA Dermatol, 161(2): 2025,147-56
Simpson EL, Bissonnette R, Chiesa Fuxench ZC, Kallender H, Sturm D, Ren H, Stein Gold LF Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies , J Dermatolog Treat, 35(1): 2024,2310633
Rau A, Silva GS, Margolis DJ, Chiesa Fuxench ZC Adult and infantile seborrheic dermatitis: update on current state of evidence and potential research frontiers , Int J Dermatol, 63(11): 2024,1495-1502
